Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

BACKGROUND Glucagon-GLP-1 dual receptor agonists have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of the IMPACT trial was to assess the effects of one such agent, pemvidutide, in patients with MASH and stage F2 or F3 fibrosis. We previously reported the 24-week primary end...

M. Noureddin, N. Alkhouri, R. Loomba et al. · 0 citations
Open access Jul 2026

Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset

Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction‐associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis.

Maria Mironova, K. Padmanabhan, David Schneider et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.